株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

萎縮型黄斑変性:パイプライン製品の分析

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 246001
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
萎縮型黄斑変性:パイプライン製品の分析 Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 136 Pages
概要

当レポートでは、萎縮型黄斑変性の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

萎縮型黄斑変性の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

萎縮型黄斑変性:企業で開発中の治療薬

萎縮型黄斑変性:大学/機関で研究中の治療薬

萎縮型黄斑変性:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

萎縮型黄斑変性:企業で開発中の製品

萎縮型黄斑変性:大学/機関で研究中の製品

萎縮型黄斑変性の治療薬開発に従事している企業

  • Aciont Inc.
  • Acucela Inc.
  • Alimera Sciences, Inc.
  • Allergan Plc
  • Apellis Pharmaceuticals, Inc.
  • アステラス製薬
  • Benitec Biopharma Limited
  • Biophytis SAS
  • Catalyst Biosciences, Inc.
  • Cell Cure Neurosciences, Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Genentech, Inc.
  • GenSight Biologics S.A.
  • GlaxoSmithKline Plc
  • Icon Bioscience, Inc.
  • Johnson & Johnson
  • Kodiak Sciences, Inc.
  • MacuCLEAR, Inc.
  • Novartis AG
  • Ophthotech Corp.
  • Orphagen Pharmaceuticals, Inc.
  • pSivida Corp.
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd.

萎縮型黄斑変性:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

萎縮型黄斑変性:最近のパイプライン動向

萎縮型黄斑変性:休止中のプロジェクト

萎縮型黄斑変性:開発が中止された製品

萎縮型黄斑変性:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8675IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016, provides an overview of the Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline landscape.

Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred or decreased central close-up and distance vision, blind spots, micropsia and straight lines look distorted. Predisposing factors include age and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 2, 14, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Dry (Atrophic) Macular Degeneration.

Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dry (Atrophic) Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dry (Atrophic) Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dry (Atrophic) Macular Degeneration Overview
  • Therapeutics Development
    • Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview
    • Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis
  • Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies
  • Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
  • Dry (Atrophic) Macular Degeneration - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dry (Atrophic) Macular Degeneration - Products under Development by Companies
  • Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes
  • Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development
    • Aciont Inc.
    • Alimera Sciences, Inc.
    • Allergan Plc
    • Apellis Pharmaceuticals Inc
    • Astellas Pharma Inc.
    • Benitec Biopharma Limited
    • Biophytis SAS
    • Catalyst Biosciences, Inc.
    • Cell Cure Neurosciences, Ltd.
    • Charlesson LLC.
    • Foamix Pharmaceuticals Ltd.
    • Genentech Inc
    • GenSight Biologics S.A.
    • GlaxoSmithKline Plc
    • Icon Bioscience, Inc.
    • Inception Sciences, Inc.
    • Johnson & Johnson
    • Kodiak Sciences Inc.
    • MacuCLEAR Inc
    • MeiraGTx Limited
    • Novartis AG
    • Ophthotech Corp.
    • Orphagen Pharmaceuticals, Inc.
    • pSivida Corp.
    • Samumed LLC
    • Sucampo Pharmaceuticals, Inc.
    • Sun Pharma Advanced Research Co Ltd
  • Dry (Atrophic) Macular Degeneration - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APL-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacincaptad pegol sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBAMD-231 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brimonidine tartrate implant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLG-561 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLT-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNTO-2476 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Age Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EG-30 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FMX-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Ocular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-030 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-933776 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICR-14967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KSI-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lampalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MA09-hRPE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MC-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methotrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OCU-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONL-1204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OpRegen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OpRegen Plus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RC-1 Alpha - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RST-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Dry AMD and Wet AMD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for AMD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Dry AMD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tesidolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • unoprostone isopropyl - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dry (Atrophic) Macular Degeneration - Dormant Projects
  • Dry (Atrophic) Macular Degeneration - Discontinued Products
  • Dry (Atrophic) Macular Degeneration - Product Development Milestones
    • Featured News & Press Releases
      • Aug 30, 2016: RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics
      • May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences
      • Apr 12, 2016: BIOPHYTIS to Present Pre-Clinical Data on BIO 201 at Upcoming Scientific Conference
      • Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia
      • Oct 01, 2013: Roche to present data on Lampalizumab at investor event
      • Aug 27, 2013: Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration
      • Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials
      • May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells
      • Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy
      • Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy
      • Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells
      • Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference
      • Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone
      • Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells
      • Aug 02, 2012: ACT Announces First Dry Age-Related Macular Degeneration Patient Treated With Higher Dosage Of Embryonic Stem Cell-Derived RPE Cells
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016
  • Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Allergan Plc, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Astellas Pharma Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Biophytis SAS, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Genentech Inc, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics S.A., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Inception Sciences, Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Johnson & Johnson, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR Inc, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Samumed LLC, H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2016
  • Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H2 2016
  • Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..2), H2 2016
  • Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016
  • Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top